UnitedHealth stock rising from the dead, posts further gains

UnitedHealth Group (UNH) shares climbed approximately 4% in pre-market trading, driven by the company's reaffirmation of its 2025 adjusted EPS guidance and an internal estimate that 78% of its Medicare Advantage members will be in four-star or higher-rated plans. This rebound offers relief after a turbulent year for UNH, which saw its stock decline significantly from an April peak, Q2 adjusted EPS plunge due to surging healthcare utilization, and a projected medical care ratio exceeding 89%. While the recent Amedisys acquisition is strategically important, its near-term dilutive impact means the reaffirmed guidance and strong MA ratings are crucial for investor confidence amidst ongoing operational pressures.

Analysis

UnitedHealth Group's shares exhibited a notable 4% pre-market increase to $332.10, driven by the company's reaffirmation of its 2025 adjusted earnings per share guidance. This renewed confidence is further supported by an internal projection that 78% of its Medicare Advantage members will be in plans rated four-stars or higher by CMS, a critical factor for government reimbursements and member enrollment. This positive development must be viewed in the context of a highly challenging year, during which the stock plummeted from an April peak above $630 to a low of $234.60. The pressure stems from surging healthcare utilization, which caused second-quarter adjusted EPS to fall to $4.08 from $6.80 year-over-year and pushed the projected full-year medical care ratio to exceed 89%. Furthermore, the recent acquisition of Amedisys, while strategically important, is expected to be modestly dilutive to near-term adjusted earnings, adding another layer of complexity for investors weighing the positive forward guidance against severe recent operational headwinds.

Key Decisions for Investors

• Consider the reaffirmed 2025 EPS guidance and strong Medicare Advantage star rating projections as key positive signals that may suggest management's confidence in overcoming current cost pressures.
• Investors should closely monitor the medical care ratio in upcoming quarters, as the projection exceeding 89% remains the single largest risk to profitability and the achievability of the company's guidance.
• Factor in the near-term earnings dilution from the Amedisys acquisition, weighing the immediate financial drag against the long-term strategic value of expanding into home healthcare.